Trial Profile

A Phase I/IIa Dose Escalation Study Evaluating the Safety and Efficacy of Autologous CD34+-Enriched HSPCs Genetically Modified With Human Interferon-α2 in Patients With Glioblastoma Multiforme and Unmethylated MGMT Gene Promoter

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha 2 gen e therapy-GenentaScience (Primary) ; Busulfan; Carmustine; Lenograstim; Plerixafor; Thiotepa
Indications Glioblastoma
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms TEM-GBM; Tem-Gbm_001 Study
Sponsors Genenta Science

09 Feb 2026 Planned End Date changed from 9 Dec 2025 to 30 Jun 2026.
09 Feb 2026 Planned primary completion date changed from 9 Dec 2025 to 30 Jun 2026.
01 Jul 2025 Status changed from recruiting to active, no longer recruiting, according to a Genenta Science media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com